CoMentis Overview

  • Founded
  • 2004
Founded
  • Status
  • Out of Business
  • Employees
  • 33
Employees
  • Latest Deal Type
  • Liquidation

CoMentis General Information

Description

Developer of small-molecule drugs designed to treat central nervous system disorders. The company's drugs cover the research and development spectrum from initial drug design through manufacturing and clinical trials, enabling healthcare professionals to treat age-related macular degeneration (AMD) and other cognitive disorders easily.

Contact Information

Website
www.comentis.com
Formerly Known As
Athenagen
Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Primary Office
  • 400 Oyster Point Boulevard
  • Suite 226
  • South San Francisco, CA 94080
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

CoMentis Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Bankruptcy: Liquidation 01-Jun-2017 00000 Completed Out of Business
5. Later Stage VC (Series E) 16-Mar-2016 00.00 00000 0000 Completed Generating Revenue
4. Later Stage VC (Series D) 15-May-2008 0000 00000 00000 Completed Generating Revenue
3. Later Stage VC (Series C) 24-Oct-2007 0000 0000 00000 Completed Generating Revenue
2. Early Stage VC (Series B) 06-Sep-2007 $50M $71M 000.00 Completed Generating Revenue
1. Early Stage VC (Series A) 11-Aug-2006 $21M $21M 000.00 Completed Generating Revenue
To view CoMentis’s complete valuation and funding history, request access »

CoMentis Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series E 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series D 00,000,000 00.000000 0.00 00.00 00.00 00 00.00 0.000
Series C 00,000,000 00.000000 0.00 00.00 00.00 00 00.00 0.00
Series B 92,543,030 $0.000100 8.5% $0.43 $0.43 1x $0.43 37.51%
Series A 34,669,123 $0.000100 8.5% $0.47 $0.47 1x $0.47 14.05%
To view CoMentis’s complete cap table history, request access »

CoMentis Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of small-molecule drugs designed to treat central nervous system disorders. The company's drugs cover the rese
Drug Discovery
South San Francisco, CA
33 As of 2015
00000
000000000000 00000

00000000

is nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate veli
0000 000000000
Kalamazoo, MI
00 As of 0000
0000
0000000000 0 0000

00000000

enderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupi
0000 000000000
Blue Bell, PA
0 As of 0000
00.00
0000000000 0 00.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

CoMentis Competitors (48)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Metabolic Solutions Development Venture Capital-Backed Kalamazoo, MI 00 0000 0000000000 0 0000
00000000 000000000 Venture Capital-Backed Blue Bell, PA 0 00.00 0000000000 0 00.00
000000000 Formerly VC-backed South San Francisco, CA 00000 000.00 00000000000
0000000 Venture Capital-Backed Framingham, MA 00 000.00 00000000000 000.00
0000000000 Formerly VC-backed Cambridge, MA 00 0000 000000&0 0000
You’re viewing 5 of 48 competitors. Get the full list »

CoMentis Patents

  • 71

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 000

    Granted

  • 000

    Pending

  • 000

    Expiring in next 12 mo

CoMentis Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-2873678-A1 Chromane compounds Abandoned 30-May-2012 0000000000
JP-2015518048-A Chroman compounds Pending 30-May-2012 0000000000
AU-2013267555-A1 Chromane compounds Abandoned 30-May-2012 0000000000
US-8975415-B2 Chromane compounds Expired - Fee Related 30-May-2012 0000000000 0
US-20140179695-A1 Chromane compounds Granted 30-May-2012 C07D413/14
To view CoMentis’s complete patent history, request access »

CoMentis Executive Team (11)

Name Title Board Seat Contact Info
Terence Kelly Ph.D Chief Executive Officer, Board Member, Chief Scientific Officer & President
You’re viewing 1 of 11 executive team members. Get the full list »

CoMentis Board Members (6)

Name Representing Role Since
John Higgins Self Chairman 000 0000
Terence Kelly Ph.D CoMentis Chief Executive Officer, Board Member, Chief Scientific Officer & President 000 0000
You’re viewing 2 of 6 board members. Get the full list »

CoMentis Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

CoMentis Investments & Acquisitions (3)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000000 01-May-2017 00000 0000 00000 Business/Productivity Software
00000 14-Aug-2006 0000000000 Drug Discovery 000000 00
Osprey Pharmaceutical Company 13-Apr-2006 Merger/Acquisition Drug Discovery 0000 0000
To view CoMentis’s complete investments and acquisitions history, request access »

Ready to get started?

Request a free trial